JSPR.US Jasper Therapeutics Inc

Healthcare Biotechnology USA Stocks
13.68 USD
Close of Nov 15, 2026
9.45 62.10
Market cap
USD 15.2M
P/E
-
P/B
10.75x
ROE
-556.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is JSPR.US undervalued?

Graham number

The Graham number of Jasper Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Jasper Therapeutics Inc fundamental analysis

No fundamental analysis for Jasper Therapeutics Inc yet.

Jasper Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Jasper Therapeutics Inc

Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. Its products in various stages of development include KP-104, a dual-complement inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) which is in Phase 2; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated dis…

Full company profile